CN116829541A - 肽受体放射性核素治疗 - Google Patents

肽受体放射性核素治疗 Download PDF

Info

Publication number
CN116829541A
CN116829541A CN202180092891.6A CN202180092891A CN116829541A CN 116829541 A CN116829541 A CN 116829541A CN 202180092891 A CN202180092891 A CN 202180092891A CN 116829541 A CN116829541 A CN 116829541A
Authority
CN
China
Prior art keywords
conjugate
peg
peptide
peg moiety
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180092891.6A
Other languages
English (en)
Chinese (zh)
Inventor
朱莉·L·苏特克利夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN116829541A publication Critical patent/CN116829541A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180092891.6A 2020-12-04 2021-12-03 肽受体放射性核素治疗 Pending CN116829541A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063121762P 2020-12-04 2020-12-04
US63/121,762 2020-12-04
PCT/US2021/061886 WO2022120226A1 (en) 2020-12-04 2021-12-03 Peptide receptor radionuclide therapy

Publications (1)

Publication Number Publication Date
CN116829541A true CN116829541A (zh) 2023-09-29

Family

ID=81853616

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180092891.6A Pending CN116829541A (zh) 2020-12-04 2021-12-03 肽受体放射性核素治疗

Country Status (9)

Country Link
US (1) US20240131206A1 (https=)
EP (1) EP4255891A4 (https=)
JP (1) JP2023552383A (https=)
KR (1) KR20230117581A (https=)
CN (1) CN116829541A (https=)
AU (1) AU2021390552A1 (https=)
CA (1) CA3203175A1 (https=)
MX (1) MX2023006483A (https=)
WO (1) WO2022120226A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025160502A1 (en) 2024-01-26 2025-07-31 The Regents Of The University Of California Peptide receptor radionuclide therapy

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN88102026A (zh) * 1987-03-11 1988-09-28 密歇根大学 化学-放射-免疫-结合物
US20090087377A1 (en) * 2007-03-27 2009-04-02 Ali Azhdarinia Compositions for targeted imaging and therapy
US20120015899A1 (en) * 2008-10-25 2012-01-19 Plant Bioscience, Limited Modified plant virus particles and uses therefor
US20120328516A1 (en) * 2009-12-30 2012-12-27 Mcparland Brian J Method of radiotherapy using a radiolabelled rgd peptide
WO2018098390A1 (en) * 2016-11-23 2018-05-31 Cancer Targeted Technology Llc Albumin-binding psma inhibitors
CN109091683A (zh) * 2018-08-10 2018-12-28 北京大学 一种用于整合素αvβ6靶向的环状多肽放射性药物及其制备方法
CN109563135A (zh) * 2016-06-13 2019-04-02 加利福尼亚大学董事会 α(V)β(6)整合素结合肽及其使用方法
US20200283532A1 (en) * 2017-04-24 2020-09-10 Cancer Research Technology Limited Tumour-targeting peptide variants
US20200306391A1 (en) * 2017-05-30 2020-10-01 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2945945C (en) * 2014-04-15 2023-10-03 The Regents Of The University Of California Bi-terminal pegylated integrin-binding peptides and methods of use thereof
WO2021226432A2 (en) * 2020-05-08 2021-11-11 The Regents Of The University Of California Methods of detecting and treating lung damage in respiratory-related viral infections

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN88102026A (zh) * 1987-03-11 1988-09-28 密歇根大学 化学-放射-免疫-结合物
US20090087377A1 (en) * 2007-03-27 2009-04-02 Ali Azhdarinia Compositions for targeted imaging and therapy
US20120015899A1 (en) * 2008-10-25 2012-01-19 Plant Bioscience, Limited Modified plant virus particles and uses therefor
US20120328516A1 (en) * 2009-12-30 2012-12-27 Mcparland Brian J Method of radiotherapy using a radiolabelled rgd peptide
CN109563135A (zh) * 2016-06-13 2019-04-02 加利福尼亚大学董事会 α(V)β(6)整合素结合肽及其使用方法
WO2018098390A1 (en) * 2016-11-23 2018-05-31 Cancer Targeted Technology Llc Albumin-binding psma inhibitors
US20200283532A1 (en) * 2017-04-24 2020-09-10 Cancer Research Technology Limited Tumour-targeting peptide variants
US20200306391A1 (en) * 2017-05-30 2020-10-01 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
CN109091683A (zh) * 2018-08-10 2018-12-28 北京大学 一种用于整合素αvβ6靶向的环状多肽放射性药物及其制备方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
HUA ZHANG等: "Preclinical Evaluation of an Integrin αvβ6‑Targeted Photodynamic Therapy", BIOCONJUGATE CHEM., vol. 36, 13 June 2025 (2025-06-13), pages 1516 - 1526 *
LINA Y. HU等: "Characterization and Evaluation of 64Cu-Labeled A20FMDV2 Conjugates for Imaging the Integrin αvβ6", MOL IMAGING BIOL, vol. 16, 22 January 2014 (2014-01-22), pages 567 - 577 *
NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION: "Polyprotein [Foot-and-mouth disease virus O].", pages 34 - 55, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/protein/AAT01760.1?report=genbank&log$=protalign&blast_rank=1&RID=2DEHWBT1016> *
SVEN H. HAUSNER等: "Evaluation of [64Cu]Cu-DOTA and [64Cu]Cu-CB-TE2A Chelates for Targeted Positron Emission Tomography with an avb6-Specific Peptide", MOLECULAR IMAGING, vol. 8, no. 2, 30 April 2009 (2009-04-30), pages 111 - 121 *
SVEN H. HAUSNER等: "The Effects of an Albumin Binding Moiety on the Targeting and Pharmacokinetics of an Integrin αvβ6-Selective Peptide Labeled with Aluminum [18F]Fluoride", MOL IMAGING BIOL, vol. 22, 7 May 2020 (2020-05-07), pages 1543 - 1552 *
TANUSHREE GANGULY等: "Preclinical Evaluation of 68Ga- and 177Lu-Labeled Integrin avb6-Targeting Radiotheranostic Peptides", J NUCL MED, vol. 64, 7 October 2022 (2022-10-07), pages 639 *

Also Published As

Publication number Publication date
WO2022120226A1 (en) 2022-06-09
EP4255891A4 (en) 2026-03-18
AU2021390552A9 (en) 2024-06-20
AU2021390552A1 (en) 2023-06-29
CA3203175A1 (en) 2022-06-09
US20240131206A1 (en) 2024-04-25
JP2023552383A (ja) 2023-12-15
EP4255891A1 (en) 2023-10-11
KR20230117581A (ko) 2023-08-08
MX2023006483A (es) 2023-07-20

Similar Documents

Publication Publication Date Title
US11160887B2 (en) Compositions for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
JP2024541595A (ja) 放射線医薬的治療方法及び使用
JP2017503763A (ja) Ｇｃｃ発現細胞を撮像するための化合物及び組成物
US20250295821A1 (en) Targeted radiopharmaceutical for tumor and its use in the imaging-guided combination therapy of targeted radiotherapy and immunotherapy
CN118290400A (zh) 一种fap结合剂、同位素络合物及其用途
CN116829541A (zh) 肽受体放射性核素治疗
US20240342322A1 (en) Netrin-1 detection, companion test and therapy based on radiations
KR20260040237A (ko) Psma 표적 방사성 리간드 치료 요법
US20190160188A1 (en) Radiolabeled Alpha-Melanocyte Stimulating Hormone Hybrid Peptide for Melanoma Targeting
JP2024500829A (ja) 治療診断剤として使用するための放射性標識α－Ｖβ－３及び／又はα－Ｖβ－５インテグリンアンタゴニスト
CN118891066A (zh) 用于癌症治疗和成像的复合物
HK40103039A (zh) 肽受体放射性核素治疗
WO2025160502A1 (en) Peptide receptor radionuclide therapy
WO2026083399A1 (en) Conjugates and use of same for theranostics
WO2024206972A1 (en) Compounds and combinations for diagnosing and treating melanoma and methods related to the same
JP2015083546A (ja) 癌の原発巣・骨転移の検査・治療用放射性標識薬剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination